Federal Commission for the Protection against Sanitary Risk

Maremi Group, a Mexican Corporation, Creates a Branch in the Middle East

Retrieved on: 
Thursday, July 20, 2023
Federal Commission for the Protection against Sanitary Risk, Information technology, Marketing, Film industry, Drug

Mexico City, Mexico--(Newsfile Corp. - July 20, 2023) - The Middle East branch of the Mexican Maremi Group, which operates in the real estate, pharmaceutical, marketing, information technology, security, and financial industries, has officially opened its doors.

Key Points: 
  • Mexico City, Mexico--(Newsfile Corp. - July 20, 2023) - The Middle East branch of the Mexican Maremi Group, which operates in the real estate, pharmaceutical, marketing, information technology, security, and financial industries, has officially opened its doors.
  • Under the name MAREMI MENA (Middle East and North Africa), this new headquarters will begin operations.
  • In the initial phase of the expansion, Maremi Group will team up with Middle Eastern pharmaceutical firms to import goods into the markets of Latin America.
  • The Maremi Group intends to conclude deals with both the public and private sectors while also expanding production at its pharmaceutical laboratory.

Mexico Needs mpox Vaccine, Says AHF and Vaccine Advocates in The Lancet Letter

Retrieved on: 
Wednesday, March 8, 2023
LGBTQ+, AIDS, Health, Consumer, Infectious Diseases, Pharmaceutical, Science, Bangladesh Technical Education Board, Travel, Public sector, Federal Commission for the Protection against Sanitary Risk, Mpox, CDC, Ministry of Health (Saudi Arabia), Public health emergency of international concern, Infection, Vaccine, European Medicines Agency, MPOX, Ministry, Centers for Disease Control and Prevention, AIDS Healthcare Foundation, Risk, HIV, Disease, STI, AHF, WHO, Director general, Death, Public, NGO, COVID-19, Letter, Policy, Viral disease, Trade Wars, COFEPRIS, World Health Organization, Oregon Higher Education Coordinating Commission, SSA, Ministry of Health, Pharmaceutical industry, Medical device, EU, Lancet

The European Medicines Agency and the US FDA have also authorized the use of the vaccine.

Key Points: 
  • The European Medicines Agency and the US FDA have also authorized the use of the vaccine.
  • Among the authors of this study is the highest decision-maker in public health in Mexico, Dr. Hugo López-Gatell, Undersecretary of Health.
  • The letter was accepted and finally published by the same magazine in its correspondence section titled " MPOX vaccines are needed in Mexico ,” on March 6, 2023.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

Retrieved on: 
Thursday, February 9, 2023
Research, Hearing, Patient, Drug discovery, Federal Commission for the Protection against Sanitary Risk, Cisplatin, ARO, Pharmaceutical industry, Otorhinolaryngology

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

Key Points: 
  • BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.
  • The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline.
  • Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy.
  • Podium 26 | Development of DB-020, a Locally Administered Product for Protection Against Cisplatin-Induced Ototoxicity

Sofwave Gains Market Approval For SUPERB™ Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico — the Second Largest Aesthetic Medical Market in Latin America

Retrieved on: 
Monday, January 23, 2023
TASE, Medicine, Food, Federal Commission for the Protection against Sanitary Risk, Food and Drug Administration, Safety, Hospital, Dermatology, Trade Wars, Physician, Medical tourism, Cellulite, SAN, COFEPRIS, Growth, Pharmaceutical industry, Health

SAN CLEMENTE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced market approval for Sofwave’s™ SUPERB Technology in Mexico.

Key Points: 
  • SAN CLEMENTE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced market approval for Sofwave’s™ SUPERB Technology in Mexico.
  • Approval was granted by Mexico’s Food and Drug Administration, the Federal Commission for the Protection from Sanitary Risks (COFEPRIS), a division of the Mexico’s Ministry of Health.
  • “The tailwinds associated with Mexico’s growing aesthetic medical device market which is growing at more than 8% annually is expected to benefit our anticipated brand launch.
  • Additionally, Sofwave has also recently received U.S. Food and Drug Administration clearance to expand SUPERB’s treatment indications to be used for the short-term improvement in the appearance of cellulite.

Latin America Companion Diagnostics Market Report to 2028 - Featuring Almac, Biocartis, Danaher, GE Healthcare and Qiagen Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Medical Devices, Health, Federal Commission for the Protection against Sanitary Risk, Growth, Government, Federalism commission (Germany), Trade Wars, Physician, Pharmaceutical industry

In Mexico, initiatives undertaken to reduce approval time for clinical trials are anticipated to surge the adoption of companion diagnostics devices.

Key Points: 
  • In Mexico, initiatives undertaken to reduce approval time for clinical trials are anticipated to surge the adoption of companion diagnostics devices.
  • Thus, these factors are expected to contribute to the expansion of the companion diagnostics market.
  • In Rest of Latin America, countries like Argentina, Peru, Chile, and Columbia are expected to witness consistent growth over the forecast period.
  • As per estimates, the in-vitro and molecular diagnostics industry is expanding at a rapid pace, which is estimated to augment the companion diagnostics market's growth.

The Worldwide Electronic Article Surveillance Industry is Projected to Reach $1.22 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Other Retail, Technology, Fashion, Luxury, Retail, Other Technology, Security, Department Stores, CAGR, Theft, Industry, Others, Radio frequency, Ansoff Matrix, Observation, Federal Commission for the Protection against Sanitary Risk, Supermarket, Competitive analysis, Antenna (radio), COVID-19, Growth, USD, Emotion, Investment, Microwave, Market development, SWOT, Geography, Impact, Porter's five forces analysis, Component, Risk, Medical device, Retail, Risk management, Pharmaceutical industry, Technology, Tag

The Global Electronic Article Surveillance Market is estimated to be USD 1.02 Bn in 2022 and is projected to reach USD 1.22 Bn by 2027, growing at a CAGR of 3.7%.

Key Points: 
  • The Global Electronic Article Surveillance Market is estimated to be USD 1.02 Bn in 2022 and is projected to reach USD 1.22 Bn by 2027, growing at a CAGR of 3.7%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Electronic Article Surveillance Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Electronic Article Surveillance Market.
  • The report offers a comprehensive evaluation of the Global Electronic Article Surveillance Market.

BioElectronics’ RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico

Retrieved on: 
Wednesday, March 30, 2022
Company, Sale, Forward-looking statement, BIEL, General manager, Neurosurgery, Health, Industry, Bioelectronics, GLOBE, Back pain, Global-Tech Appliances, Inc. v. SEB S.A., FDA, OTC, Patient, Elective surgery, Pharmaceutical industry, Audit, MD, Federal Commission for the Protection against Sanitary Risk

FREDERICK, MD, March 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation ( https://www.bielcorp.com/ (OTC: BIEL) today announced its distribution partner in Mexico has received authorization from Mexican FDA (Cofepris), which allows for the importation of the RecoveryRx device into Mexico.e

Key Points: 
  • FREDERICK, MD, March 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation ( https://www.bielcorp.com/ (OTC: BIEL) today announced its distribution partner in Mexico has received authorization from Mexican FDA (Cofepris), which allows for the importation of the RecoveryRx device into Mexico.e
    Novro Med S.A. de C.V. has contracted for the exclusive distribution rights for RecoveryRx in Mexico.
  • After several months of working with Cofepris, we can proudly announce we have obtained the regulatory approval for RecoveryRx.
  • We are very excited that we can bring this drug-free pain therapy device to patients in Mexico.
  • For more information, visit www.globaltech.com.mx
    About BioElectronics: BioElectronics Corporation is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx Devices for post-operative pain and wound care.

Diagnos A.I. retinal screening technology expands into international markets

Retrieved on: 
Thursday, August 5, 2021
Efficiency, Industry, ADK, Optometry, Multimedia, Eye, Toronto Stock Exchange, Severe cognitive impairment, Hospital, Algorithm, Chum, Artificial intelligence, Ai, Retina, Jody Vance, Capillary, Federal Commission for the Protection against Sanitary Risk, Diabetes, EC, Food and Drug Administration, Clinic, FRA, Solution, Anomaly, Population, Technology, Vein, Levon Larents, Cara, Medicine, Stroke, Partnership, Artery, Health Canada, Aneurysm, BCI, Patient safety, Adoption, Atherosclerosis, Blockade IMARC, Patient, Bleeding, AV, Risk, Adult, Iris, Disease, Drug, Medical device, Medical imaging, Telescopic sight, Cryptocurrency, Pharmaceutical industry

CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.

Key Points: 
  • CARA's artificial intelligence-based image enhancement algorithms provide sharper, clearer, retinal images that can then be analyzed for anomalies.
  • "IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail," stated said Eric Babin, President of IRIS.
  • "Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with Diagnos."
  • Diagnos' technology can inform a patient that she is at risk for a heart attack or stroke.

INVO Bioscience Obtains Regulatory Approval to Import INVOcell Into Mexico

Retrieved on: 
Monday, March 1, 2021
Fertility medicine, Federal Commission for the Protection against Sanitary Risk, Fertility clinic, Infertility, Fertility, Health

SARASOTA, Fla., March 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, today announced the Company has received approval by COFEPRIS to import INVOcell into Mexico.

Key Points: 
  • SARASOTA, Fla., March 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, today announced the Company has received approval by COFEPRIS to import INVOcell into Mexico.
  • In late 2020, INVO Bioscience established a joint venture focused on establishing fertility centers dedicated to offering INVOcell, with the initial center, called Positib Fertility, to be located in the city of Monterrey, Mexico.
  • Steve Shum, CEO of INVO Bioscience, commented, "We are extremely pleased to have received approval by COFEPRIS to begin importing INVOcell into Mexico.
  • Dr. Arredondo successfully sold his U.S.-based fertility clinics in 2019 and is now focused on bringing the INVOcell solution to Mexico.

Pure Jamaican's Pharma Division Seven10 Nears Start of Exportation of Pharmaceutical Cannabis Ingredients to Mexico With Mexican Senate's Approval of Cannabis Legislation

Retrieved on: 
Thursday, December 3, 2020
Medicinal plants, Entheogens, Euphoriants, Herbalism, Health sciences, Branches of biology, Health care, Appetite stimulants, Cannabis, Federal Commission for the Protection against Sanitary Risk, Medical cannabis, Food and Drug Administration

The legislation now passes to the House for expected final approval.

Key Points: 
  • The legislation now passes to the House for expected final approval.
  • Mexico, with its 130 million residents, is a key market for Pure Jamaican's distribution of cannabinoid active pharmaceutical ingredients (APIs) into LATAM and the EU.
  • The legislation confirms that COFEPRIS (the equivalent of the FDA in Mexico) will oversee medicinal and pharmaceutical cannabis.
  • A Mexican Cannabis Institute will be created to be fully functional in January 2022 to oversee the recreational market.